As the country’s healthcare system is dealing with the unprecedented COVID-19 pandemic, Bristol Myers Squibb has made the decision to delay commercialization of ZEPOSIA based on what’s in the best health interest of our patients, customers, and employees. We will continue to monitor the environment and will partner with the neurology community to inform timing of product availability. Learn more about our company’s response.

Register for More Information

For updates about ZEPOSIA, including product availability, please provide your contact information below.


Are You a Healthcare Professional?